MADHAVBAUG

Vaidya Sane Ayurved Laboratories Share Price

₹150.00 +5 (3.45%)

21 Nov, 2024 14:16

SIP TrendupStart SIP in MADHAVBAUG

Start SIP

Performance

  • Low
  • ₹150
  • High
  • ₹150
  • 52 Week Low
  • ₹107
  • 52 Week High
  • ₹266
  • Open Price₹150
  • Previous Close₹145
  • Volume4,000

Investment Returns

  • Over 1 Month + 11.94%
  • Over 3 Month + 14.59%
  • Over 6 Month -18.72%
  • Over 1 Year -39.16%
SIP Lightning

Smart Investing Starts Here Start SIP with Vaidya Sane Ayurved Laboratories for Steady Growth!

Invest Now

Vaidya Sane Ayurved Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 158
  • P/B Ratio
  • 2.8
  • Average True Range
  • 7.15
  • EPS
  • 1.65
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.97
  • RSI
  • 50.02
  • MFI
  • 75.77

Vaidya Sane Ayurved Laboratories Financials

Vaidya Sane Ayurved Laboratories Technicals

EMA & SMA

Current Price
₹150.00
+ 5 (3.45%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹145.70
  • 50 Day
  • ₹144.80
  • 100 Day
  • ₹151.06
  • 200 Day
  • ₹169.85

Resistance and Support

143.33 Pivot Speed
  • R3 151.67
  • R2 148.33
  • R1 146.67
  • S1 141.67
  • S2 138.33
  • S3 136.67

What's your outlook on Vaidya Sane Ayurved Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vaidya Sane Ayurved Laboratories has an operating revenue of Rs. 198.50 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 3% needs improvement, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 10 which is a POOR score indicating inconsistency in earnings, a RS Rating of 18 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Hospitals and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vaidya Sane Ayurved Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results & Others To consider other business matters.
2024-05-26 Audited Results
2023-05-27 Audited Results & Dividend
2022-11-10 Quarterly Results
Date Purpose Remarks
2022-11-18 INTERIM Declaration of Interim dividend at the rate of 0.25 per share {2.5%}.

Vaidya Sane Ayurved Laboratories F&O

Vaidya Sane Ayurved Laboratories Shareholding Pattern

66.34%
22.24%
11.42%

About Vaidya Sane Ayurved Laboratories

  • NSE Symbol
  • MADHAVBAUG
  • BSE Symbol
  • Managing Director
  • Dr. Rohit Madhav Sane
  • ISIN
  • INE0JR301013

Similar Stocks to Vaidya Sane Ayurved Laboratories

Vaidya Sane Ayurved Laboratories FAQs

Vaidya Sane Ayurved Laboratories share price is ₹150 As on 21 November, 2024 | 14:02

The Market Cap of Vaidya Sane Ayurved Laboratories is ₹157.7 Cr As on 21 November, 2024 | 14:02

The P/E ratio of Vaidya Sane Ayurved Laboratories is As on 21 November, 2024 | 14:02

The PB ratio of Vaidya Sane Ayurved Laboratories is 2.8 As on 21 November, 2024 | 14:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23